BOSTON, MA
4 risk indicators measuring financial stability and operational resilience
Sign in with your work email to view Tuckman-Chang indicators
Sign In — Free (10 views/day)NORTH EAST ALS CONSORTIUM INC, founded in 2005, is a community nonprofit in the Medical Research sector that reported $2.1M in total revenue in fiscal year 2024. Revenue surged 53% from the prior year, signaling strong growth momentum. The organization ran a surplus of $1.5M, a strong 73% operating margin.
THE MISSION OF NORTH EAST ALS CONSORTIUM (NEALS) IS TO TRANSLATE SCIENTIFIC ADVANCES INTO CLINCICAL RESEARCH AND NEW TREATMENTS FOR PEOPLE WITH AMYOTROPHIC LATERAL SCLEROSIS (ALS) AND MOTOR NEURON DISEASE (MND) AS RAPIDLY AS POSSIBLE.
THE ANNUAL NEALS MEETING SERVES AS AN OPPORTUNITY FOR NEALS RESEARCHERS TO LIAISE WITH LEADING ALS AND MND SCIENTISTS, GOVERNMENT SPONSORS, ACADEMIC PARTNERS, AND PHARMACEUTICAL COMPANIES IN ORDER TO...
THE ANNUAL NEALS MEETING SERVES AS AN OPPORTUNITY FOR NEALS RESEARCHERS TO LIAISE WITH LEADING ALS AND MND SCIENTISTS, GOVERNMENT SPONSORS, ACADEMIC PARTNERS, AND PHARMACEUTICAL COMPANIES IN ORDER TO DISCUSS POTENTIAL TREATMENTS, TO REVIEW CURRENT RESEARCH ACTIVITIES, AND TO SHARE SCIENTIFIC UPDATES. THE NEALS SCIENCE ADVISORY BOARD IS RESPONSIBLE FOR ADVISING THE NEALS EXECUTIVE COMMITTEE AND NEALS MEMBERS ABOUT THE SCIENTIFIC BASIS OF NEALS RESEARCH ACTIVITIES. IN ADDITION, NEALS HAS BUILT AN EXTENSIVE ALS SAMPLE REPOSITORY AND MAINTAINED SEVERAL TRIAL DATABASES. IN THE SPIRIT OF COLLABORATION, WE MAKE RESOURCES SUCH AS THESE WIDELY AVAILABLE TO INVESTIGATORS CONDUCTING RESEARCH IN ALS.
Financial Health Score (300–850) · Liquidity · Solvency · Sustainability · Efficiency
Sign in to view Trantor Score and financial metrics
Liquidity (40%) • Solvency (30%) • Sustainability (20%) • Efficiency (10%)
Sign In — Free (10 views/day)| 2024 | 2023 | Change | |
|---|---|---|---|
| Revenue | $2,066,070 | $1,347,482 | +0.5% |
| Expenses | $554,594 | $1,069,037 | -0.5% |
| Net Income | $1,511,476 | $278,445 | +4.4% |
Comprehensive financial analysis: Altman Z-Score, liquidity, solvency, sustainability, efficiency, and growth metrics
Financial Distress Indicator
Liquidity & Cash Position
Sign in to view all financial metrics
Altman Z-Score • Liquidity Ratios • Solvency Analysis • Growth Indicators • Efficiency Metrics
Sign In| Name | Title | Hours/Week | Role | Reportable Comp | Other Comp | Total |
|---|---|---|---|---|---|---|
| ROBERT H BROWNMD DPHIL | SAB, CHAIR | 1.00 |
Director
|
$0 | $0 | $0 |
| GALE KITTLE | CLINICAL EVALUATOR MEMBER | 1.00 |
Director
|
$0 | $0 | $0 |
| JEFFREY ROTHSTEINMDPHD | SAB, CHAIR | 1.00 |
Director
|
$0 | $0 | $0 |
| TIMOTHY MILLER MD PHD | SAB, CHAIR | 1.00 |
Director
|
$0 | $0 | $0 |
| JINSY ANDREWS MD MSC | CO-CHAIR | 5.00 |
Officer
Director
|
$0 | $0 | $0 |
| CHRISTINA FOURNIER | INVESTIGATOR MEMBER | 1.00 |
Director
|
$0 | $0 | $0 |
| NICOLE TURCOTTE | COORDINATOR MEMBER | 1.00 |
Director
|
$0 | $0 | $0 |
| MATTHEW HARMS | INVESTIGATOR MEMBER | 1.00 |
Director
|
$0 | $0 | $0 |
| SABRINA PAGANONI | INVESTIGATOR MEMBER | 1.00 |
Director
|
$0 | $0 | $0 |
| ZACHARY SIMMONS | INVESTIGATOR MEMBER | 1.00 |
Director
|
$0 | $0 | $0 |
| JAMES BERRY | CO-CHAIR | 5.00 |
Officer
Director
|
$0 | $0 | $0 |
| CARLY ALLEN | DIRECTOR OF OPERATION | 40.00 |
Officer
|
$0 | $0 | $0 |
| Year | Revenue | Expenses | Assets | Net Income |
|---|---|---|---|---|
| 2024 | $2,066,070 | $554,594 | $3,081,868 | $1,511,476 |
| 2023 | $1,347,482 | $1,069,037 | $1,517,173 | $278,445 |
| 2023 | $1,571,264 | $1,057,037 | $1,608,873 | $514,227 |
| 2022 | $1,108,820 | $893,513 | $1,089,210 | $215,307 |
| 2021 | $886,426 | $593,913 | $897,067 | $292,513 |
| 2020 | $616,014 | $487,454 | $588,932 | $128,560 |
| 2019 | $902,463 | $734,252 | $527,443 | $168,211 |
| 2018 | $458,378 | $490,158 | $338,838 | $-31,780 |
Compare NORTH EAST ALS CONSORTIUM INC with other nonprofits in Massachusetts and across the country.